HepatoPro PPC

The Maehurst Oracle Mehurst Logo
The most valuable thing you can give your cells is energy
Retail price Save 25%
$50.00 $37.50
Supplement Facts  
Serving Size 1 softgel  
Amount Per Serving  
Calories 10  
Calories from Fat 10  
Total Fat 1 g  
Polyenylphosphatidylcholine [Unsaturated phosphatidylcholine from highly purified soy bean extract] 900 mg  
Other ingredients: gelatin, medium chain triglycerides, sorbitol, glycerin, ethanol, purified water, silica.

Contains soybeans.

Dosage and Use
Take one (1) softgel two to three times daily with or without food, or as recommended by a healthcare practitioner.

Do not purchase if outer seal is broken or damaged.
When using nutritional supplements, please consult with your physician if you are undergoing treatment for a medical condition or if you are pregnant or lactating.
HepatoPro PPC (Polyunsaturated Phosphatidylcholine)
900 mg, 60 softgels Item #: 01393
Scholarly article on the benefits of PPC. ◄Click Here
The liver is a large glandular organ, whose functions include decomposition of red blood cells, plasma protein synthesis, hormone production, secretion of bile, and conversion of sugars into glycogen, which it stores. The liver is also responsible for processing many vitamins and nutrients into a form that can be utilized by the body, as well as detoxification of various substances. Modern living involves daily exposure to substances that are toxic to our bodies, which imposes a heavy load on the liver. Therefore, a healthy liver is critical to well-being. It is more important to ensure that the liver is being maintained at its functional best for optimal health.

Endogenous phospholipid is an integral part of all cell membranes and essential for their structural and functional integrity. The chemical structure of an extract from soybeans called PPC (polyenylphosphatidylcholine) corresponds to that of endogenous phospholipid and integrates in the cell membrane, becoming the cell’s constitutive element. PPC possesses functional superiority because of its content of unsaturated fatty acids. PPC has antioxidant, cytoprotective, and fluid-regulating effects and has been shown to enhance cell membrane function throughout the body.

It is believed that PPC’s beneficial effect is based on its ability to be incorporated into liver cell membranes to help restore its structure and the functioning of corresponding enzymes. This results in an increase in membrane fluidity and transport activity across the membrane.

PPC also has strong antioxidant properties, which means it may reduce oxidative stress (cellular changes that generate free radicals), may help protect the liver by modulating its immune response.

PPC is also incorporated into blood lipoproteins, helping to extend its benefits beyond the liver to promote arterial health.

Mounting evidence suggests that PPC supplementation beneficially supports the critical process of reverse cholesterol transport. This process is a well-documented function of high-density lipoprotein (HDL) that involves the transport of cholesterol from the arterial walls to the liver for processing.

Research also supports PPC’s critical role in helping to reduce LDL oxidation. In fact, a growing body of research shows that PPC can help maintain healthy lipoprotein profiles in those already within normal range.

HepatoPro contains PPC (polyenylphosphatidylcholine). Each 900-mg PPC softgel is well-absorbed when taken orally and has no known contraindications, side effects, or drug interactions.
If you take aspirin daily, read this!
Stomach protection Page 1
  (Editors note: The cardio-protective benefits of aspirin are substantial. In addition to reducing abnormal arterial blood clot formation, aspirin suppresses a dangerous pro-inflammatory agent called C-reactive protein. The latest finding about heart attack risk shows that C-reactive protein causes a lethal inflammatory cascade on the inner arterial wall. What happens is that C-reactive protein induces atherosclerotic plaque on the arterial wall to burst open like popcorn, blocking a coronary artery and causing a heart attack. Aspirin specifically suppresses C-reactive protein. Now that PPC supplements are available, taking low-dose aspirin can be made a lot safer for those who take it as a preventive.)

The consumption of non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin in our society is greater than any other drug class because of their relative effectiveness in the treatment of pain and inflammation. Recently published evidence shows that those who take NSAIDs have lower risks of Alzheimer's disease, cardiovascular disease and certain cancers. It appears that some of the common diseases of aging are caused by a chronic inflammatory cascade and that daily NSAID ingestion affords considerable protection against these disorders.

A major concern with NSAID drugs, though, relates to their well-established ability to induce gastrointestinal injury in the forms of erosion, bleeding, ulceration and perforation. Few people realize that GI toxicity from NSAIDs is the most frequent adverse drug event in the U.S., according to some estimates. The facts are alarming (Raskin JB, 1999; Wolfe MM et al., 1999):

  • NSAIDs are used regularly by at least 13 million Americans with arthritic conditions, leading to 16,500 NSAID-related deaths annually (similar to the number of deaths from AIDS).
  • NSAID use increases the relative risk of serious gastrointestinal events three-to-fourfold, and higher for the elderly.
  • 30-60% of chronic NSAID users develop gastroduodenal erosions; 5-30% of chronic users develop ulcers.
  • One third of patients over age 60 with bleeding from peptic ulcers are on NSAIDs.
  • Two thirds of patients over age 60 with GI perforations are on NSAIDs.
  • Over 100,000 people are hospitalized annually in the U.S. for serious GI complications from NSAID use.
  • The mortality rate for patients hospitalized for upper GI bleeding from NSAIDs is 5-10%.
  • GI toxicity from NSAID use is the 15th most common cause of death in the U.S.
  • Advanced age is a primary risk factor for adverse GI events from NSAID use, and the risk increases steadily with age.
This "silent epidemic" appears without symptoms in up to 40% of cases of NSAID-induced erosive gastritis. While 10-20% of NSAID users have indigestion (dyspepsia), this is not a reliable indicator of mucosal injury. Damage to the gastric epithelium begins within minutes of taking an NSAID, and hemorrhages and erosions follow within hours. In most people the gastric mucosa adapt over time, but studies show that 60-100% of patients on NSAIDs for 1 to 2 weeks develop submucosal hemorrhage, superficial erosions, erythema (inflammation of mucous membranes), or blood in the stool. Moreover, NSAID toxicity extends to the small intestine and large bowel, as manifested in silent ulcerations, colitis-like conditions, and aggravation of inflammatory bowel disease. 
  Page 2
Doses of aspirin as low as 30 mg suppress the production of protective prostaglandins in the gastric mucosa. In addition, aspirin's direct contact with the gastrointestinal tract interferes with the hydrophobic "non-wettable" properties that protect the underlying epithelium from gastric acid and other toxic substances. This characteristic seems to be attributable to an extracellular lining of phospholipids, which are synthesized in surface mucus cells of the stomach. Aspirin and other NSAIDs can rapidly transform the gastric mucosa from a non-wettable to a wettable state, thereby increasing the tissue's susceptibility to the corrosive actions of gastric acid.

A study on experimentally induced gastric ulcers in rats (Dunjic BS, et al., 1993) showed that mucosal lesions were significantly reduced by a single dose of PPC given before or after the injury factor, which in this study was ethanol or an NSAID.

A recent clinical trial compared the GI effects of aspirin to those of aspirin complexed with PPC (Anand BS et al., 1999). Sixteen healthy subjects were given either ten doses of aspirin or ten doses of the aspirin/PPC complex over a 72 hour period. After a "washout" period, subjects were switched over to the other medication for a 72 hour period.

Researchers counted the number of gastroduodenal erosions in each subject. Those taking aspirin had an average of 8.75 erosions, while those taking the aspirin/PPC complex averaged only 2.81 erosions. The protective effect of PPC was most apparent in those who were most susceptible to aspirin injury, and did not interfere with the therapeutic activity of the aspirin.